Acarbose
Acarbose (alpha-glucosidase inhibitor)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Precose, Glucobay, Prandase
Produced one of the largest male lifespan effects in the mouse programme built to catch false positives, and has almost no human geroscience data at all.
Overview
Acarbose blocks the enzymes that break starch into absorbable sugar, so carbohydrate passes further down the gut and the post-meal glucose spike is flattened. It is an old and cheap diabetes drug, and it is the most interesting compound in the NIA Interventions Testing Program that almost nobody outside geroscience discusses. Across three separate cohorts, four doses and two starting ages, it extended median male lifespan by between 6% and 22%, and it still worked when started at 16 months, which is late middle age for a mouse. The female effect is much smaller and the dose-response is flat, meaning more did not do more. The human picture is the mirror image: decades of use in diabetes, a cardiovascular outcome trial that was flatly null, and total geroscience exposure amounting to an 8 person pilot and a 28 person crossover that was terminated for lack of funding.
Mechanism of action
Competitively inhibits intestinal alpha-glucosidases, slowing the breakdown of complex carbohydrates and blunting the postprandial glucose rise. Undigested carbohydrate reaching the colon is fermented by gut bacteria, which produces the characteristic side effects and may itself contribute to the metabolic effects.
Human evidence
Substantial for diabetes and glucose control, and close to nonexistent for ageing. Acarbose has been prescribed for decades, so its safety and tolerability profile is well characterised, but nobody has run a geroscience trial of it.
- ACE, randomised and double-blind in 6,522 people with coronary heart disease and impaired glucose tolerance over 5 years: the primary cardiovascular composite was null, hazard ratio 0.98, p = 0.73. It did reduce progression to type 2 diabetes.
- STOP-NIDDM reported a cardiovascular benefit that made acarbose's reputation. Independent methodologists have challenged its conduct and reporting, and the supporting meta-analysis was authored by employees of the manufacturer pooling that manufacturer's own trials.
- Total geroscience exposure in humans: a pilot in 8 participants and a crossover in 28 that was terminated for lack of funding. No trial has tested acarbose for any ageing endpoint in people.
- Tolerability is the practical constraint. In the label's own trial data flatulence occurred in 74% on acarbose against 29% on placebo, diarrhoea in 31% against 12%, and abdominal pain in 19% against 9%.
What this does not tell you: The mouse result is strong and it is a mouse result. Nothing has been measured about acarbose and human ageing, and the one large human outcome trial that exists was negative on its primary endpoint.
Reading the research record
Acarbose is the compound that best illustrates why this site separates species. The Interventions Testing Program was built specifically to catch results that do not replicate: the same protocol runs at three independent sites, and its published record is mostly a list of compounds that failed. Acarbose is one of the few that worked, worked repeatedly, and still worked when started late in life. That is a genuinely unusual result and it deserves attention.
It is also entirely in mice, and the sex difference is large enough to matter, with males benefiting far more than females. The flat dose-response, where quadrupling the dose did not increase the effect, is worth noting too: it suggests the mechanism saturates, which is informative but also makes the human dose-finding question harder.
On the human side the record runs the other way. The cardiovascular claim rests on a trial whose conduct has been formally disputed, and the much larger and later ACE trial found nothing on its primary endpoint. There is no patent to defend and no sponsor with a reason to fund a geroscience trial, which is the same economics that empties the trial record across most of this site.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2003 to 2019, counted from the citation list on this page. The newest citation on file is from 2019, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, prescription route in 3, not approved in 0. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2014
Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
The first Interventions Testing Program cohort reporting acarbose extending male median lifespan, in genetically heterogeneous mice across three independent sites.
Aging Cell - Animal2019
Acarbose improves health and lifespan in aging HET3 mice
Replication and extension across doses and starting ages, including a late start at 16 months that preserved much of the effect in males.
Aging Cell - Human2017
Effect of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
6,522 patients followed 5 years: no reduction in the primary cardiovascular composite (HR 0.98, p = 0.73), while confirming a reduction in progression to diabetes.
Lancet Diabetes and Endocrinology - Human2003
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
The trial that generated acarbose's cardiovascular reputation. Its validity has been formally challenged over differential dropout, blinding and reporting, and the later and much larger ACE trial did not confirm it.
JAMA
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Gastrointestinal effects are the near-universal report, particularly flatulence and bloating, and they are dose-dependent and worst with high-starch meals.
- Users commonly describe starting at a very low dose and increasing slowly over weeks, and taking it only with the largest carbohydrate meal rather than with every meal.
- Continuous glucose monitor users frequently report a visibly flattened post-meal curve, which is the drug doing exactly what it is known to do and is not evidence of any ageing effect.
Sources: Longevity forums and continuous glucose monitoring communities. Uncontrolled self-report, included for expectations and side effects rather than as evidence.
Frequently asked questions
Why is acarbose interesting for longevity?
Because it produced one of the largest male lifespan extensions in the NIA Interventions Testing Program, the multi-site mouse programme designed to weed out results that do not replicate, and it worked even when started in late middle age. Most compounds tested in that programme fail.
Does it work in humans for ageing?
Nobody knows, because nobody has tested it. The total human geroscience record is a pilot in 8 people and a 28 person crossover terminated for lack of funding. Its large human trials were about diabetes and cardiovascular disease, and the largest of those was null on its primary endpoint.
Why did the effect differ so much between male and female mice?
That is unexplained, and it is common in this literature rather than unique to acarbose. Several compounds in the same programme show large sex differences in lifespan effect, and the mechanisms behind them are not established.
What are the side effects?
Overwhelmingly gastrointestinal, because the whole mechanism is delivering undigested carbohydrate to gut bacteria. In the manufacturer's own trial data flatulence occurred in 74% of people taking it against 29% on placebo.